Novartis Ag (NVS) Shareholder Rockefeller Financial Services INC Decreased Stake

April 16, 2018 - By Sheila Anderson

Novartis AG (NYSE:NVS) Corporate Logo

In Novartis Ag (NVS) was decreased the stake held by Rockefeller Financial Services Inc. The decrease is 4.76% according to 2017Q4 Securities and Exchange filling. The company’s stock declined 4.22% with the market as Rockefeller Financial Services Inc sold 50,324 shares. The institutional investor is holding 1.01 million shares, compared to the 1.06 million from the previous quarter. And the reported value of the major pharmaceuticals company is $84.49M for the 2017Q4. $190.53 billion is Novartis Ag’s market cap. NVS reached $81.17 on during the last trading session after $0.13 change.Novartis AG has volume of 1.55M shares. Since April 16, 2017 NVS has risen 5.79% and is uptrending. NVS underperformed the S&P 500 by 5.76%.

Rockefeller Financial Services Inc manages about $6.34B US Long portfolio. It upped its stake in Spark Therapeutics Inc. (NASDAQ:ONCE) by 352,719 shares to 353,983 shares, valued at $18.20M in 2017Q4, according to the filing. Rockefeller Financial Services Inc has risen its stake in Medidata Solutions Inc. (NASDAQ:MDSO) and also increased its holding in Ishares Msci Japan Etf by 172,029 shares in the quarter, for a total of 188,271 shares.

Analysts await Novartis AG (NYSE:NVS) to report earnings on April, 24. They expect $1.32 earnings per share, up 16.81 % or $0.19 from last year’s $1.13 per share. NVS’s profit will be $3.10 billion for 15.37 P/E if the $1.32 EPS becomes a reality. After $1.20 actual earnings per share reported by Novartis AG for the previous quarter, Wall Street now forecasts 10.00 % EPS growth.

Novartis AG (NYSE:NVS) Ratings Coverage

Total analysts of 4 have positions in Novartis AG Common Stock (NYSE:NVS) as follows: 0 rated it a “Buy”, 2 with “Sell” and 2 with “Hold”. The positive are 0. Since October 23, 2017 according to StockzIntelligence Inc Novartis AG Common Stock has 5 analyst reports. On Monday, October 23 the firm earned “Market Perform” rating by Leerink Swann. On Wednesday, October 25 Barclays Capital downgraded Novartis AG (NYSE:NVS) to “Sell” rating. On Thursday, January 25 Leerink Swann maintained Novartis AG (NYSE:NVS) with “Market Perform” rating. In Friday, February 2 report Cowen & Co maintained the stock with “Hold” rating. On Wednesday, December 6 the rating was downgraded by Bank of America to “Sell”.

Novartis AG (NYSE:NVS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: